HOME >> MEDICINE >> NEWS
18 Millionth Chemical Substance Entered In World's Largest Database Of ChemicalInformation

New Substance, Found In Patent, May Help With Asthma, Migraine, And Pain Treatments

COLUMBUS, Ohio--Chemical Abstracts Service added the 18 millionth chemical substance to its database--the world's largest collection of chemical information. The substance, identified in a patent application from Merck and Co., is an intermediate compound in the preparation of tachykinin receptor antagonists which may be useful in the treatment of inflammatory diseases, pain or migraine and other ailments.

The substance's name is (1S-cis)-2-Phenyl-3-cyclohexene-1-carboxylic acid and it is identified by the CAS Registry Number 207110-49-4.

Chemical Abstracts Service reviews and summarizes chemistry research in patents, conference proceedings and more than 8,000 scientific journals; in the process, CAS scientists identify new chemical substances mentioned in new scholarly reports, and capture them in the CAS Registry file.

New chemical substances are added to the CAS Registry at the rate of approximately one new record every 9 seconds. (The great majority of chemical substances mentioned in scientific literature are never encountered by the general public, nor produced in significant quantities. Nevertheless, some of these substances may eventually lead to new medicine, materials, or other important discoveries.)

The 18 millionth substance was registered on June 15, 1998, selected from a World Intellectual Property Organization patent application of April 30, 1998 from Merck & Co., Inc.

Chemical Abstracts Service is a division of the American Chemical Society, the world's largest scientific society, with a membership of more than 155,000 chemists and chemical engineers. CAS has published Chemical Abstracts since 1907.


'"/>

Contact: Kirk Monroe
k_monroe@acs.org
202/872-4445
American Chemical Society
22-Jun-1998


Page: 1

Related medicine news :

1. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
2. Chemicals in tattoo inks need closer scrutiny
3. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
4. Chemicals found in cherries may help fight diabetes
5. Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment
6. Health benefits of citrus topic at American Chemical Society meeting in Philadelphia
7. Chemical brain scans may help reassure brain tumor patients
8. US DoE awards $4 million in funding to Stevens Center for MicroChemical Systems
9. Chemical & Engineering News 80th anniversary issue highlights periodic table
10. Chemical turns stem cells into neurons say scientists at Scripps Research Institute
11. Brookhaven spotlights: News from the March 2003 American Chemical Society Meeting

Post Your Comments:
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , Dallas ... Department of Plastic Surgery at UT Southwestern Medical Center, ... blindness resulting from the use of facial aesthetic ... study, along with ideas for treatment and prevention in ... to see increasing reports of blindness as a result ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 2015 Skin cancer is one of the ... caught early. Forefront Dermatology and Dermatology Associates of Wisconsin want ... before it spreads so they are hosting a free skin ... 8:30am - 12:30pm. , “If we can see the ... concern, that could become cancerous,” said Dr. Ken Katz, who ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, ... Inc. (NYSE: VRX and ... completed the previously announced acquisition of ... a specialty pharmaceutical company that offers ...  (rifaximin) 550 mg, RUCONEST ®  (C1 esterase inhibitor ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
Cached News: